Yeah, I know, I think with the new tech, multigene, and small synthetic molecule stuff, it's too soon for a big pharma to put a price tag on OncoSec, not impossible, but it presses down on my buyout enthusiasm I thought about for so long. I also am happy to be wrong and see them pull off a great deal that would the developmental potential of their tech, much better than $15 a share.
Market Data 
Markets 
AI
